Assessment of Pathological Prostate Cancer Characteristics in Men with Favorable Biopsy Features on Predominantly Sextant Biopsy

European Urology

Volumn 55, Issue 3, 2009, Pages 617-628

  Chun, Felix K H ^a,b   Suardi, Nazareno ^a,c   Capitanio, Umberto ^a,c   Jeldres, Claudio ^a   Ahyai, Sascha ^b   Graefen, Markus ^b   Haese, Alexander ^b   Steuber, Thomas ^b   Erbersdobler, Andreas ^b   Montorsi, Francesco ^c   Huland, Hartwig ^b   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF HAMBURG   (Germany)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Minimal disease; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 58849105513     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.099     Document Type: Article

References (30)

1. Miller D.C., Gruber S.B., Hollenbeck B.K., Montie J.E., and Wei J.T. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98 (2006) 1134-1141
2. Klotz L. Active surveillance for prostate cancer: for whom?. J Clin Oncol 23 (2005) 8165-8169
3. Briganti A., Chun F.K.-H., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1027 (discussion 1026-7)
4. Chun F.K., Briganti A., Shariat S.F., et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 98 (2006) 329-334
5. Chun F.K.-H., Karakiewicz P.I., Briganti A., et al. Prostate cancer nomograms: an update. Eur Urol 50 (2006) 914-926 (discussion 926)
6. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
7. Nakanishi H., Wang X., Ochiai A., et al. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance. Cancer 110 (2007) 2441-2447
8. Chun F.K., Briganti A., Jeldres C., et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 43 (2007) 536-543
9. Chun F.K.-H., Briganti A., Lebeau T., et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 49 (2006) 273-279 (discussion 278-9)
10. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
11. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713-2719
12. Griffin C.R., Yu X., Loeb S., et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 178 (2007) 860-863
13. Chun F.K.-H., Steuber T., Erbersdobler A., et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 49 (2006) 820-826
14. Bastian P.J., Mangold L.A., Epstein J.I., and Partin A.W. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101 (2004) 2001-2005
15. Winkler M.H., Khan F.A., Hoh I.M., et al. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit. BJU Int 93 (2004) 725-729
16. Chan T.Y., Chan D.Y., Stutzman K.L., and Epstein J.I. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?. J Urol 166 (2001) 2181-2184
17. Aus G., Damber J.E., Khatami A., Lilja H., Stranne J., and Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165 (2005) 1857-1861
18. Shukla-Dave A., Hricak H., Kattan M.W., et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 99 (2007) 786-793
19. Kundu S.D., Roehl K.A., Yu X., Antenor J.A., Suarez B.K., and Catalona W.J. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 177 (2007) 505-509
20. Boccon-Gibod L.M., Dumonceau O., Toublanc M., Ravery V., and Boccon-Gibod L.A. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 48 (2005) 895-899
21. Boccon-Gibod L.M., de Longchamps N.B., Toublanc M., Boccon-Gibod L.A., and Ravery V. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer. J Urol 176 (2006) 961-964 (discussion 963-4)
22. Harnden P., Naylor B., Shelley M.D., Clements H., Coles B., and Mason M.D. The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression?: a systematic review and meta-analysis. Cancer 112 (2008) 971-981
23. Carter H.B., Kettermann A., Ferrucci L., Landis P., and Metter E.J. Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70 (2007) 685-690
24. Allan R.W., Sanderson H., and Epstein J.I. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 170 (2003) 370-372
25. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
26. Noguchi M., Stamey T.A., McNeal J.E., and Yemoto C.M. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166 (2001) 104-110 (discussion 109-10)
27. Singh H., Canto E.I., Shariat S.F., et al. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol 171 (2004) 204-209
28. Walz J., Graefen M., Chun F.K.-H., et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 50 (2006) 498-505
29. Postma R., Schröder F.H., van Leenders G.J.L.H., et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam: a comparison of two rounds of screening. Eur Urol 52 (2007) 89-97
30. Sengupta S., Blute M.L., Bagniewski S.M., et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 101 (2008) 170-174